In this article, we will list the 5 Cheap Large Cap Stocks to Buy Now. Please visit 8 Cheap Large Cap Stocks to Buy Now if you would like to see the extended list and the methodology behind it.
5. Synchrony Financial (NYSE:SYF)
On April 9, 2026, Wells Fargo lowered the price target on Synchrony Financial (NYSE:SYF) to $95 from $100 and maintained an Overweight rating. Wells Fargo said investor focus is shifting from geopolitical risk to concerns around AI-driven job impacts, noting sentiment appears bearish, while adding that credit performance and card spending remain solid and stimulus effects are expected to offset higher gas prices, with banks likely to maintain a constructive view on consumers.
On April 6, 2026, Seaport Research lowered its price target on Synchrony Financial (NYSE:SYF) to $84 from $95 previously and maintained a Buy rating on the shares. Seaport Research said it reduced estimates due to lower-than-expected net interest margin expansion in 2026.
Similarly, Barclays analyst Terry Ma lowered the price target on Synchrony Financial (NYSE:SYF) to $82 from $93 previously and maintained an Overweight rating on the shares. Terry Ma said valuations across the consumer finance group have declined below historical averages amid macro uncertainty, while noting favorable risk/reward among preferred names.
Synchrony Financial (NYSE:SYF) provides consumer credit products and financial services in the United States.
4. MetLife, Inc. (NYSE:MET)
On April 9, 2026, UBS raised the price target on MetLife, Inc. (NYSE:MET) to $102 from $98 and maintained a Buy rating. UBS said the update reflects changes across the North American life insurance group ahead of Q1 earnings, noting continued focus on disability margins with “relatively limited wiggle-room” given cyclicality and economic uncertainty, while rolling its valuation to 2027 estimates.
On the same day, MetLife Investment Management said it originated approximately $26B in private fixed income transactions in 2025, bringing total assets under management on its platform to $144.7B as of December 31, 2025. The platform includes private corporate and infrastructure debt, asset-based finance, residential loans, and sustainable finance, with originations including $8.9B in residential credit, $6.8B in corporate debt, $5.7B in infrastructure debt, and $4.5B in asset-based finance.
On April 8, 2026, Barclays lowered its price target on MetLife to $89 from $92 and maintained an Overweight rating. Barclays said premium growth and broker organic growth are expected to remain sluggish, but noted that margins and capital deployment should continue to support book value growth.
MetLife, Inc. (NYSE:MET) provides insurance, asset management, and financial services globally.
3. The Hartford Insurance Group, Inc. (NYSE:HIG)
On April 9, 2026, Cantor Fitzgerald analyst Ryan Tunis lowered the price target on The Hartford Insurance Group, Inc. (NYSE:HIG) to $160 from $165 and maintained an Overweight rating. Ryan Tunis said the update reflects changes across the insurance group ahead of Q1 earnings, noting soft market conditions are more reflected in reinsurer valuations than in specialty and commercial lines.
On the same day, The Hartford Insurance Group, Inc. (HIG) appointed Natalie Burns as head of Enterprise Sales & Distribution, effective May 1, reporting to Tracey Ant. Natalie Burns will oversee relationships with key distribution partners and coordinate across Personal and Business Insurance and Employee Benefits sales teams, replacing Stephen Screen, who has moved to a role in Global Specialty.
On April 8, 2026, Barclays lowered its price target on The Hartford Insurance Group, Inc. (HIG) to $159 from $162 and maintained an Overweight rating. Barclays said premium growth and broker organic growth are expected to remain sluggish, but noted margins and capital deployment should continue to support book value growth.
The Hartford Insurance Group, Inc. (NYSE:HIG) provides insurance and financial services to individuals and businesses.
2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
On April 9, 2026, BofA raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $42 from $38 and maintained a Buy rating. BofA said the update reflects changes made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.
On March 30, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that its applications for a proposed biosimilar to Xolair, oromalizumab, have been accepted for review by both the U.S. FDA and the European Medicines Agency. The filings include a Biologics License Application and a Marketing Authorization Application and cover all approved indications of the reference product, including moderate-to-severe persistent allergic asthma.
On the same day, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA approval of Ponlimsi as a biosimilar to Prolia. The company said the approval covers all indications of the reference product, including treatment of postmenopausal women with osteoporosis at high risk for fracture, supported by data showing comparable efficacy, safety, and immunogenicity.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops and markets generic and biopharmaceutical medicines globally.
1. Delta Air Lines, Inc. (NYSE:DAL)
On April 9, 2026, TD Cowen raised the price target on Delta Air Lines, Inc. (NYSE:DAL) to $84 from $76 and maintained a Buy rating after updating its model following a Q1 update. TD Cowen said fuel volatility highlights the durability of the company’s business and could raise the long-term RASM floor as weaker competitors pull back, while noting net debt is at its lowest level since pre-COVID.
Similarly, Citi raised its price target on Delta Air Lines, Inc. (NYSE:DAL) to $79 from $77 previously and maintained a Buy rating on the shares. Citi said the company delivered a Q1 earnings beat supported by strong demand trends, reinforcing its position across key market segments.
On April 8, 2026, Delta Air Lines, Inc. (NYSE:DAL) reported Q1 adjusted EPS of 64c compared to the 56c consensus estimate, with revenue of $15.85B versus $14.82B consensus. CEO Ed Bastian said results were “more than 40 percent higher” year over year despite higher fuel costs and operational disruptions, highlighting strong performance and $1.3B in profit-sharing payouts.
Delta Air Lines, Inc. (NYSE:DAL) provides passenger and cargo air transportation services globally.
While we acknowledge the potential of DAL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DAL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Stocks That Beat Earnings Estimates and 10 Best 52-Week Low NASDAQ Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
